Today's Date: March 28, 2024
Bill Introduced in Minnesota Would Increase Access To Genetic Testing   •   More $10-a-day child care spaces   •   Paralyzed Veterans of America to honor former Senator Elizabeth Dole with 2024 Gordon H. Mansfield Congressional Leadership Awar   •   American Water Charitable Foundation Announces National Partnership With American Red Cross With $250,000 Donation   •   Gale Primary Sources Release Four New Archives Devoted to Contributions from Underrecognized Communities   •   Pushing Policy: Women Uniting for Legislative Change; Four Trailblazing women at the forefront of the Quad Caucus   •   Federal Home Loan Bank of Dallas and Wells Fargo Bank Award $850K for Rio Manor Apartments Renovation   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS   •   John Legend to Perform at City Year Los Angeles’ 13th Annual Spring Break Event   •   University of Phoenix Receives Arizona Veteran Supportive Campus Recertification   •   UC Berkeley FHL Vive Center Teams Up with BeamNG   •   Fastenal Releases 2024 Environmental, Social, and Governance (ESG) Report   •   Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   Planet to Provide Carbon Mapper, Inc. with Hyperspectral Data Until 2030   •   Torrid Reports Fourth Quarter and Fiscal 2023 Results and Initiates Fiscal 2024 Guidance   •   Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™   •   BNSF Railway builds upon safety record by utilizing virtual reality for training   •   80 M/other Artists Converge for MICAfest 2024 in Northampton, MA this May   •   PMI Foods Gives Easter Donation of 15,000 Pounds of Prime Rib to New Life Church in Arkansas
Bookmark and Share

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

CARLSBAD, Calif. , March 20 /Businesswire/ - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held April 21st, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA. The presentation, “Phase 1/2a Study of OpRegen in Patients with Geographic Atrophy (GA),” will be presented by Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology at Hadassah-Hebrew University Medical Center. RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration between Lineage, and Roche and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with geographic atrophy secondary to age-related macular degeneration (ClinicalTrials.gov Identifier: NCT05626114).

The 2023 Retinal Cell and Gene Therapy Innovation Summit, "Defining the Preclinical to Clinical Roadmap" will feature presentations that emphasize clinical trial design for gene and cell-based therapies. Representatives from the biotech and pharma industries will come together with physicians and scientists to discuss rapidly emerging ocular gene and cell therapies and strategize how to move the most advanced retinal disease therapy options forward.

About the Foundation Fighting Blindness

The Foundation Fighting Blindness was established in 1971 by a passionate group of families driven to find treatments and cures for inherited retinal diseases that were affecting their loved ones. Today, the Foundation Fighting Blindness is the world’s leading private funder of retinal disease research. That funding has been a driving force behind the progress toward cures, including the identification of more than 270 genes linked to retinal disease, and the launch of over 40 clinical trials for potential treatments. For more information, please visit https://www.fightingblindness.org/ or follow the association on Twitter @FightBlindness.

About Geographic Atrophy

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterized by severe loss of visual function. GA is a leading cause of adult blindness in the developed world, affecting at least 5 million people globally. There are two forms of advanced AMD: neovascular AMD and GA. GA and neovascular AMD can occur simultaneously in the same eye, and patients treated for neovascular AMD may still go on to develop GA. GA typically affects both eyes.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.


STORY TAGS: California, Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Conference, Product/Service, Event, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News